VANCOUVER, Feb. 27 /PRNewswire-FirstCall/ -- Mr. David Scott, Chairman of the Special Committee of the board of directors of AnorMED Inc. (TSX:AOM, AMEX:AOM) has responded to a letter from Felix J. Baker contained in a filing of a further amendment, made February 23, 2006, to a Schedule 13D filing with the United States Securities and Exchange Commission by Felix J. Baker and Julian C. Baker. A copy of Mr. Scott's response can be found on the Company's website at http://www.anormed.com/. The Special Committee has made several attempts to reach a consensual arrangement with Mr. Baker and hopes that Mr. Baker will cooperate so that a Special Meeting is not required. The Company's proposed Board and its position on issues raised by the requisition will be addressed in its Proxy Circular. The Circular will be distributed to all AnorMED shareholders in March, prior to the Special Meeting of Shareholders, which will be held on April 11, 2006 in Vancouver, B.C. AnorMED is a chemistry-based biopharmaceutical company focused on the discovery, development and commercialization of new therapeutic products in the areas of hematology, HIV and oncology. The Company has a product in Phase III development, a product in Phase II development and a research program focused on a novel class of compounds that target specific chemokine receptors known to be involved in a variety of diseases including HIV. Additional information on AnorMED Inc. is available on the Company's website http://www.anormed.com/. Note: Certain of the statements contained in this press release may contain forward-looking statements or forward-looking information within the meaning of applicable securities laws, including the Ontario Securities Act, Section 27A of the U.S. Securities Act of 1933 and Section 21E of the U.S. Securities Exchange Act of 1934. Statements or information regarding strategy, future operations, future financial position, future revenues, projected costs, prospects and plans and objectives of management are forward-looking statements. The words "anticipates, "believes", "budgets", "could", estimates", expects," forecasts", "intends", "may", "plans", "projects", "schedule", "should", "will", "would" and similar expressions are intended to identify forward-looking statements or information, although not all forward- looking statements or information contain these identifying words. Plans, intentions or expectations disclosed in any forward-looking statements or information should not be read as guarantees of future results or events, and will not necessarily be accurate indications of whether or the times at or by which such results or events will be achieved. Forward-looking statements or information involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward- looking statements or information. Investors are referred to the discussion of such risks, uncertainties and other factors in AnorMED's Final Short Form Prospectus dated December 1, 2005 filed on SEDAR with Canadian securities regulatory authorities and in Exhibit 99.1 to AnorMED's Report on Form 6-K filed with the U.S. Securities and Exchange Commission on December 23, 2005. Except as required by law, AnorMED expressly disclaims any intention and undertakes no obligation to update any forwardlooking statements or information as conditions change. For further information: Dr. Michael Abrams Elisabeth Whiting, M.Sc. President & CEO VP Corporate Development & Communications Tel: 604-530-1057 Tel: 604-532-4667 E-mail: Cell: 604-763-4682 E-mail: DATASOURCE: AnorMED Inc. CONTACT: Dr. Michael Abrams, President & CEO, Tel: (604) 530-1057, E-mail: ; Elisabeth Whiting, M.Sc., VP Corporate Development & Communications, Tel: (604) 532-4667, Cell: (604) 763-4682, E-mail:

Copyright